Altimmune shares slide as the FDA flashes a red light for the IND work on their intranasal Covid-19 vaccine
The biotech says that the agency has fairly benign intentions, maintaining that regulators halted the IND application so they could get certain protocol modifications and additional CMC data. This is, however, the first time the agency has put up a red light for a vaccine developer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.